Internationally health economic evaluations (HEEs) form a legally regulated fixed component in health-care decisions. This applies particularly to the drug sector. While HEEs are never directly implemented on a 1:1 basis in reimbursement regulations, they create transparency for all stakeholders in the system. These are some of the results presented in the journal issue, which was guest-edited by the German Institute for Quality and Efficiency in Health Care (IQWiG) and compiled contributions on the experience with HEE in seven countries.

The editors selected a broad range of countries for this special issue of the German Journal for Evidence and Quality in Health Care (ZEFQ): Australia is the country with the longest experience and tradition in HEE; England and the Netherlands have internationally renowned research in HEE. Whereas health care in Germany and the Netherlands is contribution- and premium-funded and therefore corresponds to the Bismarck system, England, Australia and Sweden represent the tax-funded Beveridge system. A view on Brazil and Thailand allows for a comparison between (western) industrialized countries and emerging countries.

For more details, go to: https://www.iqwig.de/en/press/press-releases/press-releases/internationally-health-economic-evaluations-are-a-fixed-component-of-reimbursement-decisions.6417.html